Diligence memo · auto-generated · as of July 2, 2026
Opus Genetics, Inc.
Opus Genetics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Opus Genetics, Inc. operates in Biotechnology, based in Farmington Hills.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Opus Genetics, Inc. has raised $47M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $26M on 2024-10-22.
Most recent recorded round closed around 2024-10-22.
Valuation (modeled)modeled
Provath models Opus Genetics, Inc. at approximately $161M (range $52M–$272M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.96× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era. Within the normal band (96% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 48 months.
Last raise 20 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 81% of Biotechnology peers (4293 compared).
Modeled value ranks above 68% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
23 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.